Navigation Links
Human Vaccine for Herpes Virus on the Anvil

Researchers at the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences have patented a strategy for developing a human vaccine to prevent against Human Cytomegalovirus (hCMV) infection and disease.

CMV, a type of herpes virus, is the leading viral cause of birth defects and a serious problem in patients with compromised immune systems. The bodys natural immunity doesnt protect against infection by the virus, estimated to be present in 50 to 75 percent of all adults.

Until now, scientists havent been able to develop a vaccine to protect against CMV, said Deborah H. Spector, Ph.D., UCSD Professor of Cellular and Molecular Medicine and faculty member of the Skaggs School of Pharmacy and Pharmaceutical Sciences.

Using a two-pronged approach, we successfully created and tested a vaccine in a mouse model with CMV that shows enormous promise for re-directing the bodys immune system, enabling it to fight the virus, she added.

The mouse vaccine generates an immune response that protects against both infection and development of disease when the virus is present by completely disarming the viruss ability to replicate and establish a persistent infection. The work is currently online in advance of publication in the July issue of Journal of Virology.

Our approach generates an immune response that is different from the normal response to the virus, and we hope to have found an Achilles heel in the defences that the virus uses to evade the immune system, said Spector.

The virus has evolved to persist in the host by evading the immune responses either by hiding or by misdirecting the hosts immune responses. We found a way to teach the host immune system to not be tricked by the virus, Spector added.

She added that the next step is to apply this strategy to create a vaccine for use in humans.

CMV is a virus that, while carr ied by the majority of adults in the United States, can remain dormant for years, if not the lifetime, of a healthy individual. However, two percent of all children are born with the virus passed on by the mother in utero, and 15 percent of those children will show symptoms such as hearing loss, mental retardation, motor or learning disabilities. Because the hosts natural immune system can protect from the disease but cant rid the body of the virus, people remain infected and can become re-infected or infect others through saliva.

Children in day care settings, for example, or adults who are sexually active, can pass along the virus. It becomes a serious problem in developing infants during the pregnancy or in those whose immune system is compromised, such as AIDS or transplant patients, explained Spector.

When a persistent virus such as CMV infects an individual, it disarms the host immune system in two ways by hiding or masking the proteins that would normally provoke an immune response, or by fooling the immune system into mounting a response that doesnt work to eradicate the virus.

We needed a way to make the host defense system sit up and take notice, said Christopher S. Morello, Ph.D., first author of the study.

To do this, the researchers devised a vaccine with a one-two punch that combines a DNA immunization that targets T-cells to essential genes required for CMV replication, with a killed virus that prompts the bodys B-cells to generate an antibody response.

The vaccine contains the DNA of two essential genes that are essential for replication of the virus. These genes which are also found in other herpes viruses such as chicken pox or herpes simplex have the same or very similar sequence, structure and function whether in human or mouse viruses, and present a novel target for the hosts T-cells to muster forces and attack the virus. Secondly, the vaccine also contains a boost from a n inactivated virus, which generates an antibody response. Neither approach alone would give complete protection.

In mice, the vaccine not only fought the disease, but prevented the infection from being established in the first place, Morello said.

Researchers at UCSD hope to begin pre-clinical work on development of a human vaccine. If successful, an FDA-approved, commercially licensed hCMV vaccine could be administered to specific at-risk populations, such as females prior to child-bearing years, day care providers, organ transplant recipients, or as part of regular childhood immunizations.

This approach may also be valid for a number of diseases associated with persistent or latent infections, including all types of herpes-associated diseases, AIDS, or hepatitis, said Spector.

These viruses persist because immune responses generated by the viral infection are not able to eradicate the virus.


'"/>




Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Human gene number increases
4. Scientists found ancient Human Germ Killer
5. New standards for Human Research Safety
6. Human wasting disease linked to a gene
7. The Human Mad Cow Case
8. Human Growth Hormone Found To be Dangerous For Human Use
9. Human Antibody That Can Block SARS
10. Human immunity system can battle HIV.
11. Two New Human Papilloma virus (HPV) vaccines to prevent cervical cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel of ... of proceeds to two local organizations: North Chicago Animal Control and Friends and Our ... a team of authorized and trained volunteers who support rescued animals held in the ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies and ... scam operations to a halt. According to Texas Premier Locksmith, these fraudulent locksmith ...
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... The ... the holidays and winter seasons. One major study analyzing heart attacks among 138,602 ... to August of a given year. We would all agree of course–no time of ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen ... Program at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years ... three acupuncturists to help patients realize their family building goals. Acupuncture helps ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- KEY FINDINGS Patient warming and ... loss of blood during surgeries, lowering the risks ... after surgeries, and decreasing risks of SSIs. The ... warming system, surface warming systems, and intravascular warming ... at hospitals thus, lowering the healthcare costs by ...
(Date:12/7/2016)... 7, 2016 Research and Markets has announced ... User - Global Forecast to 2021" report to their offering. ... , , ... by 2021, growing at a CAGR of 7.3% during the forecast period ... prevalence of cancer and rapidly increasing geriatric population across the globe are ...
(Date:12/7/2016)... Dec. 7, 2016 DelveInsight,s, "Janus ... provides in depth insights on the pipeline ... Janus Kinase 3 (JAK3) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
Breaking Medicine Technology: